Your session is about to expire
← Back to Search
Visual Remapping for Age-Related Macular Degeneration
N/A
Recruiting
Led By Stephen Engel, Ph.D.
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Stable fixation (+/- 1 deg) using their PRL.
16 years or older
Must not have
Central vision loss of less than 5 deg diameter; scotomas that do not cover the fovea; unilateral scotomas
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
Awards & highlights
No Placebo-Only Group
Summary
This trial will test how well people with central vision loss can read with and without different kinds of remapping of missing text to different parts of the visual field, compared to people with no vision loss.
Who is the study for?
This trial is for individuals aged 16 or older with central vision loss from age-related macular degeneration. Participants must have a stable gaze within one degree using their preferred retinal locus (PRL) and be able to calibrate an eye tracker. Those with cognitive impairment, poor fixation, or insufficient central vision loss are excluded.
What is being tested?
The study measures reading performance in patients with Central Vision Loss. It compares the effectiveness of traditional remapping versus personalized remapping of text to different visual fields in aiding reading.
What are the potential side effects?
Since this trial involves non-invasive techniques like eye tracking and visual tests rather than drugs or surgery, there are no direct side effects associated with the interventions being tested.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can keep my gaze steady using my preferred retinal location.
Select...
I am 16 years old or older.
Select...
I have significant vision loss in the center of my field of view in both eyes.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have central vision loss but can still see directly in front of me.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Reading Speed for Individual Words
Reading Speed for Natural Text Samples
Reading Speed for Sentences
+3 moreSecondary study objectives
Eye fixation quality for natural text samples
Eye fixation quality for sentences
Eye fixation quality for words
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Patients with scotomaExperimental Treatment2 Interventions
No remapping (control condition), traditional remapping, personalized remapping
Group II: Normally sighted with artificial scotomaActive Control2 Interventions
No remapping (control condition), traditional remapping, personalized remapping
Find a Location
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,427 Previous Clinical Trials
1,620,465 Total Patients Enrolled
2 Trials studying Macular Degeneration
38 Patients Enrolled for Macular Degeneration
Stephen Engel, Ph.D.Principal InvestigatorUniversity of Minnesota
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are able to use an eye tracker accurately.It is not possible to properly calibrate the eye tracker for accurate measurements.I have central vision loss but can still see directly in front of me.I can keep my gaze steady using my preferred retinal location.I am 16 years old or older.I have significant vision loss in the center of my field of view in both eyes.
Research Study Groups:
This trial has the following groups:- Group 1: Patients with scotoma
- Group 2: Normally sighted with artificial scotoma
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger